Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000

Carl Zeiss Meditec-Dublin CoCe · NCT07680244

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Not applicable
Target enrollment
400
US sites recruiting
5
Study start
May 23, 2025
Record last updated
August 28, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.

Being studied: PathFinder 1.0 on CIRRUS HD-OCT

Conditions: Epiretinal Membrane; Dry Age Related Macular Degeneration; Macular Abnormalities; Retina Disease; Vitreoretinal Abnormality; Intraretinal Hyporeflective Space; Subretinal Hyporeflective Space; IS/OS (Ellipsoid Zone) Disruption; Retinal Pigment Epithelium (RPE) Elevation; Retinal Pigment Epithelium (RPE) Atrophy

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Able and willing to make the required study visits.
  • Able and willing to give written informed consent and follow study instructions.
  • Able and willing to complete ophthalmic imaging.
  • Adults 18 years of age or older.

The subject population will be comprised of two groups (all categories below pertain to the central 6x6 mm macula area):

Group A

  • Subjects with absence of macular abnormalities Group B
  • Subjects with Disruption of the vitreoretinal interface (VRI)
  • Subjects with Intraretinal hyporeflective space (IRHS)
  • Subjects with Subretinal hyporeflective space (SRHS)
  • Subjects with IS/OS (Ellipsoid Zone) disruption
  • Subjects with Retinal Pigment Epithelium (RPE) elevation
  • Subjects with Retinal Pigment Epithelium (RPE) atrophy
  • Other abnormalities

Exclusion Criteria

  • Inability to undergo the required tests.
  • Unable to give consent or follow study instructions.
  • Inability to fixate that precludes obtaining acceptable macula scans in the study eye.
  • Visudyne (verteporfin) injection within the last 48 hours in the study eye.
  • Pilocarpine or Vuity use within the last 24 hours in the study eye.
  • Dense media opacity precluding adequate visualization of the retina in the study eye.
  • Vitreous floaters that preclude obtaining acceptable scans in the study eye.

Recruiting US locations

  • Retina Associates

    Tucson, AZ 85704

    Site contact: Study Coordinator

  • Northern California Retina Vitreous Associates

    Mountain View, CA 94040

    Site contact: Study Coordinator

  • Nova Southeastern University College of Optometry

    Fort Lauderdale, FL 33328

    Site contact: Study Coordinator

  • Eyecare Medical Group

    Portland, ME 04102

    Site contact: study coordinator

  • Moyes Eye Center

    Kansas City, MO 64154

    Site contact: Study Coordinator

Study contacts (from the official record)

  • Patricia Sha, Optometrist · 925-307-1588 · patricia.sha@zeiss.com
All healthy volunteers studies in Arizona →
(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the… (NCT07680244) | Bored Studies